Aslan Pharma ADSs Fall 43%; Won't Appeal Nasdaq Delisting

Dow Jones07-16

By Stephen Nakrosis

The American depositary shares of Aslan Pharmaceuticals are trading lower on the Nasdaq Monday, after the biopharmaceutical company said it won't appeal plans to delist its stock from the exchange.

With less than an hour left in the trading day, the ADSs dropped 43% to trade at $1.42. Volume topped 1 million ADSs, above the 65-day average volume of 51,976 ADSs.

The company said that based on its non-compliance with the $1 bid price and $2.5 million stockholders' equity requirements for continued listing, the Nasdaq staff determined to delist the stock.

Aslan recently changed the ratio of its ordinary shares from one ADS representing 25 ordinary shares to one ADS representing 200 ordinary shares. Earlier Monday, the ADSs traded at $1.31, an all-time low.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 15, 2024 15:24 ET (19:24 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2451672563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-16 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451672563","market":"nz","top_or_hot":-1,"title":"Aslan Pharma ADSs Fall 43%; Won't Appeal Nasdaq Delisting","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  The American depositary shares of Aslan Pharmaceuticals are trading lower on the Nasdaq Monday, after the biopharmaceutical company said it won't appeal plans to delist its stock from the exchange. \n</p>\n<p>\n  With less than an hour left in the trading day, the ADSs dropped 43% to trade at $1.42. Volume topped 1 million ADSs, above the 65-day average volume of 51,976 ADSs. \n</p>\n<p>\n  The company said that based on its non-compliance with the $1 bid price and $2.5 million stockholders' equity requirements for continued listing, the Nasdaq staff determined to delist the stock. \n</p>\n<p>\n  Aslan recently changed the ratio of its ordinary shares from one ADS representing 25 ordinary shares to one ADS representing 200 ordinary shares. Earlier Monday, the ADSs traded at $1.31, an all-time low. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2024 15:24 ET (19:24 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aslan Pharma ADSs Fall 43%; Won't Appeal Nasdaq Delisting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAslan Pharma ADSs Fall 43%; Won't Appeal Nasdaq Delisting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 03:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  The American depositary shares of Aslan Pharmaceuticals are trading lower on the Nasdaq Monday, after the biopharmaceutical company said it won't appeal plans to delist ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2451672563","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451672563","pubTimestamp":1721071440,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The American depositary shares of Aslan Pharmaceuticals are trading lower on the Nasdaq Monday, after the biopharmaceutical company said it won't appeal plans to delist its stock from the exchange.With less than an hour left in the trading day, the ADSs dropped 43% to trade at $1.42. Volume topped 1 million ADSs, above the 65-day average volume of 51,976 ADSs.The company said that based on its non-compliance with the $1 bid price and $2.5 million stockholders' equity requirements for continued listing, the Nasdaq staff determined to delist the stock.Aslan recently changed the ratio of its ordinary shares from one ADS representing 25 ordinary shares to one ADS representing 200 ordinary shares. Earlier Monday, the ADSs traded at $1.31, an all-time low.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","QQQ":"纳指100ETF","BK4112":"金融交易所和数据",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","ASLN":"ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)","BK4585":"ETF&股票定投概念","BK4139":"生物科技","TQQQ":"纳指三倍做多ETF","BK4535":"淡马锡持仓","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"阿斯兰制药ADS下跌43%；不会对纳斯达克退市提出上诉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"NQmain":1,"NDAQ":1,"ASLN":0.9,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"MNQmain":0.6},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  The American depositary shares of Aslan Pharmaceuticals are trading lower on the Nasdaq Monday, after the biopharmaceutical company said it won't appeal plans to delist its stock from the exchange. \n\n\n  With less than an hour left in the trading day, the ADSs dropped 43% to trade at $1.42. Volume topped 1 million ADSs, above the 65-day average volume of 51,976 ADSs. \n\n\n  The company said that based on its non-compliance with the $1 bid price and $2.5 million stockholders' equity requirements for continued listing, the Nasdaq staff determined to delist the stock. \n\n\n  Aslan recently changed the ratio of its ordinary shares from one ADS representing 25 ordinary shares to one ADS representing 200 ordinary shares. Earlier Monday, the ADSs traded at $1.31, an all-time low. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2024 15:24 ET (19:24 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451672563"}